TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29799871

Group type: EXPERIMENTAL
Intervention: 1-time chlorhexidine (CHG-T1)
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: 4-time chlorhexidine (CHG-T4)
Number of subjects: 2349

Group type: COMPARATOR
Intervention: 1-time povidone iodine (PVI-T1)
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: 4-time povidone iodine (PVI-T4)
Number of subjects: 2349
Study: 26525271

Group type: EXPERIMENTAL
Intervention: IL-6 levels measured on days 1, 2, and 3 after return of spontaneous circulation
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: IL-6 levels at day 2
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: IL-6 levels at day 3
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: IL-6 levels
Number of subjects: 682
Study: 24001004

Group type: EXPERIMENTAL
Intervention: Behavioral reaction times (RTs) for categorizing objects
Number of subjects: 0
Study: 22236346

Group type: EXPERIMENTAL
Intervention: Chloroprocaine (40 mg) mixed with 12.5 μg of fentanyl
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine (35 mg) mixed with 12.5 μg of fentanyl
Number of subjects: 40
Study: 20350785

Group type: COMPARATOR
Intervention: Meloxicam 7.5 mg orally twice per day starting on the day of implant
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg orally twice per day starting 1 week prior to implant
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control group (no meloxicam)
Number of subjects: 316
Study: 18410298

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Sildenafil plus Counseling
Number of subjects: 117
Study: 17274381

Group type: EXPERIMENTAL
Intervention: Domestic idarubicin
Number of subjects: 155

Group type: COMPARATOR
Intervention: Imported idarubicin
Number of subjects: 155
Study: 12885371

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (RLX) 60 mg daily for 12 months
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (RLX)
Number of subjects: 204
Study: 11081960

Group type: EXPERIMENTAL
Intervention: CIBIC-Plus (Clinician Interview-Based Impression of Change)
Number of subjects: 0
Study: 8897116

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Drug-free depressed patients
Number of subjects: 20
Study: 1796634

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 synthesis stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of cyclooxygenase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate heart failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Severe heart failure
Number of subjects: 0
Study: 6615751

Group type: EXPERIMENTAL
Intervention: Topical antiprostaglandins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31613308

Group type: EXPERIMENTAL
Intervention: Selepressin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30153634

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 27169811

Group type: EXPERIMENTAL
Intervention: 6-week ESM intervention including feedback
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 6-week ESM intervention without feedback
Number of subjects: 90

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 90
Study: 24461278

Group type: EXPERIMENTAL
Intervention: Controlled Breathing (CB)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Peppermint Aromatherapy (AR)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control (CB)
Number of subjects: 196
Study: 22916626

Group type: EXPERIMENTAL
Intervention: Music Auditory Training (MAT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 100
Study: 19291120

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Number of subjects: 80

Group type: COMPARATOR
Intervention: Silver sulphadiazine (SD‐Ag)
Number of subjects: 80
Study: 17699835

Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine booster
Number of subjects: 386
Study: 15319388

Group type: EXPERIMENTAL
Intervention: Assisted hatching using acidic Tyrode's solution
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group (no assisted hatching)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 253
Study: 11453889

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 0.5 mg
Number of subjects: 10
Study: 9509448

Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bicarbonate haemodialysis (HD)
Number of subjects: 20
Study: 7798824

Group type: EXPERIMENTAL
Intervention: Coumadin (adjusted dosage to maintain INR between 1.5-3)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Aspirin (fixed dosage of 75 mg per day)
Number of subjects: 79
Study: 3183367

Group type: EXPERIMENTAL
Intervention: Sodium chloride (120 mmol)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sodium phosphate (122 mmol)
Number of subjects: 6
Study: 31816097

Group type: EXPERIMENTAL
Intervention: eIL-31-CuMVTT vaccine (300 µg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29991223

Group type: EXPERIMENTAL
Intervention: Scalp block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Incision-site infiltration
Number of subjects: 60
Study: 26554758

Group type: EXPERIMENTAL
Intervention: 15 g/day of alcohol
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 30 g/day of alcohol
Number of subjects: 53

Group type: COMPARATOR
Intervention: 0 g/day of alcohol (control)
Number of subjects: 53
Study: 26333496

Group type: EXPERIMENTAL
Intervention: Group counseling (8 sessions over 2 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 100
Study: 24346133

Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoate (EPA) 2g/day
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vitamins E (364mg/day) + C (1000mg/day)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: EPA + Vitamins E+C
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: EPA and Vitamins E+C (given separately)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: EPA and Vitamins E+C (combined)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High PUFA patients
Number of subjects: 99
Study: 21613574

Group type: EXPERIMENTAL
Intervention: β‐AR blockade (intravenous propranolol)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study: 18468672

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with 525 microg of venom monthly after a 6-week build-up period
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17050873

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 112
Study: 12747499

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg/day for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11125657

Group type: EXPERIMENTAL
Intervention: Post deliberation jurors
Number of subjects: 0
Study: 8648920

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 20
Study: 1552057

Group type: EXPERIMENTAL
Intervention: High-dose UVA1 irradiation (130 joules/cm2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-dose UVA1 irradiation
Number of subjects: 25

Group type: COMPARATOR
Intervention: UVA-UVB therapy
Number of subjects: 25
Study: 6496201

Group type: EXPERIMENTAL
Intervention: Increased nicotine content cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low yield cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Return to standard brand cigarettes
Number of subjects: 0
Study: 31718019

Group type: EXPERIMENTAL
Intervention: School physical education intervention (SPE)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Afterschool program intervention (ASP)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: SPE + ASP
Number of subjects: 680

Group type: COMPARATOR
Intervention: Control
Number of subjects: 680
Study: 31143214

Group type: EXPERIMENTAL
Intervention: Motivational interviewing and lifestyle-related educations
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lifestyle-related educations
Number of subjects: 54
Study: 27418241

Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) + Methotrexate (MTX)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 21
Study: 25223240

Group type: EXPERIMENTAL
Intervention: Preterm infants with birth and newborn care preparedness
Number of subjects: 32126

Group type: EXPERIMENTAL
Intervention: Preterm infants with symptoms of infection
Number of subjects: 32126

Group type: EXPERIMENTAL
Intervention: Preterm infants whose mother suffered antenatal complications
Number of subjects: 32126

Group type: EXPERIMENTAL
Intervention: Preterm births overall
Number of subjects: 32126

Group type: EXPERIMENTAL
Intervention: Preterm infants born as the first child
Number of subjects: 32126

Group type: EXPERIMENTAL
Intervention: Preterm infants in the poorest households
Number of subjects: 32126
Study: 22149257

Group type: EXPERIMENTAL
Intervention: 20 mg of fluindione
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4 mg of acenocoumarol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CYP2C9 genotype, VKORC1 genotype, body weight
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CYP2C9 genotype, VKORC1 genotype, CYP1A2 phenotype, body weight
Number of subjects: 24
Study: 20669294

Group type: EXPERIMENTAL
Intervention: LSVT®BIG (one-to-one training)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nordic Walking (WALK)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Domestic nonsupervised exercises (HOME)
Number of subjects: 60
Study: 18794727

Group type: EXPERIMENTAL
Intervention: PPARgamma agonists (muraglitazar and other 10 PPARgamma agonists)
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: PPARgamma agonists (one of three previously uncharacterized PPARgamma agonists)
Number of subjects: 730
Study: 15765299

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 14

Group type: COMPARATOR
Intervention: Historical group (pre‐imatinib era)
Number of subjects: 14
Study: 12127877

Group type: EXPERIMENTAL
Intervention: Interleukin-2 as adjunctive therapy to antiretroviral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiretroviral therapy
Number of subjects: 0
Study: 10772563

Group type: EXPERIMENTAL
Intervention: Mixed administration of DTPw-HBV and Hib vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Separate administration of DTPw-HBV and Hib vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of Hib to DTPw-HBV
Number of subjects: 0
Study: 8545872

Group type: EXPERIMENTAL
Intervention: Steroid Withdrawal (SW) group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 2403486

Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrice containing 250 ppm fluoride
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrice containing 1,000 ppm fluoride with 1% disodium azacycloheptylidene-2.2-bisphosphonate (AHBP)
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Positive control: Monofluorophosphate dentifrice (1,000 ppm fluoride)
Number of subjects: 1161
Study: 347884

Group type: EXPERIMENTAL
Intervention: Bromperidol (1 mg tablets, initial dose: 1 mg, mean dose at end: 4.47 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Haloperidol (as reference substance)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bromperidol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 60
Study: 31735487

Group type: EXPERIMENTAL
Intervention: Rehacop group (RG)
Number of subjects: 124
Study: 29331031

Group type: EXPERIMENTAL
Intervention: Bladder body injection of 100U BoNT‐A in 10 mL saline
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Trigonal injection of 100U BoNT‐A in 10 mL saline
Number of subjects: 39
Study: 28928048

Group type: EXPERIMENTAL
Intervention: Edoxaban (15mg in 5 patients, 30mg in 23 patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-edoxaban group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 60
Study: 26193635

Group type: EXPERIMENTAL
Intervention: Alefacept (two 12-week courses of 15 mg/wk i.m., separated by a 12-week pause)
Number of subjects: 49
Study: 23771104

Group type: EXPERIMENTAL
Intervention: BMS-986001 100 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BMS-986001 200 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BMS-986001 300 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BMS-986001 600 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 20188783

Group type: EXPERIMENTAL
Intervention: Vitremer Tri‐Cure Glass Ionomer System
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Freedom
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TPH Spectrum
Number of subjects: 48

Group type: COMPARATOR
Intervention: Class II cavity preparation
Number of subjects: 48
Study: 19018047

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Currently recommended follow‐up procedures
Number of subjects: 0
Study: 17690522

Group type: EXPERIMENTAL
Intervention: Wearing rubber gloves in addition to local ventilation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison group (workers from other departments)
Number of subjects: 42
Study: 13679938

Group type: EXPERIMENTAL
Intervention: recombinant granulocyte colony-stimulating factor (rG-CSF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 10752802

Group type: EXPERIMENTAL
Intervention: Additional therapy with colloid and dobutamine (5 microg/kg/min then 10 microg/kg/min) for patients with pHi <7.35
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (standard resuscitation without additional therapy)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Additional therapy with colloid and dobutamine for patients with gastric mucosal pH of > or =7.35 at admission
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (standard resuscitation without additional therapy) for patients with gastric mucosal pH of > or =7.35 at admission
Number of subjects: 210
Study: 8694326

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil infusion at lumbar level (1 microgram/mL)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil infusion at thoracic level (1 microgram/mL)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil combined with bupivacaine at thoracic level (1 mg/mL)
Number of subjects: 37
Study: 1442581

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6374885

Group type: EXPERIMENTAL
Intervention: Sclerotherapy (20 ml Aethoxysclerol 1%)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 126
Study: 31872435

Group type: EXPERIMENTAL
Intervention: Power analysis method for CRTs with K≥2 binary co‐primary endpoints
Number of subjects: 0
Study: 29429607

Group type: EXPERIMENTAL
Intervention: Personalized 'activity fingerprint' message
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no activity fingerprint)
Number of subjects: 79
Study: 27707509

Group type: EXPERIMENTAL
Intervention: Fursultiamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Benfotiamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Thiamine nitrate
Number of subjects: 24
Study: 24800998

Group type: EXPERIMENTAL
Intervention: FE 999049 (recombinant follicle-stimulating hormone from human cell line)
Number of subjects: 0
Study: 22244399

Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Open pyloromyotomy
Number of subjects: 98
Study: 20087375

Group type: COMPARATOR
Intervention: Salba (0, 7, 15 or 24 g baked into white bread)
Number of subjects: 11
Study: 17229792

Group type: EXPERIMENTAL
Intervention: Proactive chlamydia screening using mailed home‐collected specimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proactive chlamydia screening
Number of subjects: 0
Study: 16141740

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (70 units total, 40 units in the medial aspect of the heel, 30 units in the arch of the foot)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 27
Study: 11799500

Group type: EXPERIMENTAL
Intervention: MMA + IVN
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IVN
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: MMA
Number of subjects: 47

Group type: COMPARATOR
Intervention: PCA + IVN
Number of subjects: 47
Study: 10624956

Group type: EXPERIMENTAL
Intervention: Viewing three-dimensional displays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control experiments
Number of subjects: 0
Study: 7856520

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (48-hour treatment)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Isotonic glucose (placebo)
Number of subjects: 194
Study: 1835251

Group type: EXPERIMENTAL
Intervention: Paroxetine (Seroxat, Aropax)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 36
Study: 6801959

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 11

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 11
Study: 30231262

Group type: EXPERIMENTAL
Intervention: Watching a standardized videoclip during sleep induction with propofol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not watching a standardized videoclip during sleep induction with propofol
Number of subjects: 50
Study: 28975821

Group type: EXPERIMENTAL
Intervention: Long-acting blood cardioplegia (adenosine 12 mg via aortic root, followed by a single dose of long-acting solution at 14℃, 30 mL/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: St. Thomas' cardioplegia (initial 30 mL/kg at 14℃, followed by 15 mL/kg every 20 min)
Number of subjects: 100
Study: 25355310

Group type: EXPERIMENTAL
Intervention: AVP-825
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 230
Study: 24457490

Group type: EXPERIMENTAL
Intervention: Polymyxin B Hemoperfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21955930

Group type: EXPERIMENTAL
Intervention: Nicotine patches (experimental group)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: No nicotine patches (control group)
Number of subjects: 3000
Study: 19401574

Group type: EXPERIMENTAL
Intervention: First-pass imaging
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Steady-state imaging
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combined imaging (first-pass plus steady-state)
Number of subjects: 84
Study: 17341511

Group type: EXPERIMENTAL
Intervention: Concurrent feedback
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Terminal feedback
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no feedback)
Number of subjects: 36
Study: 15080061

Group type: EXPERIMENTAL
Intervention: Intraprostatic injection of Chuanshentong (6 ml mixed with lidocaine, once a day for 6 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo injection containing lidocaine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 11448705

Group type: EXPERIMENTAL
Intervention: Stress management and relaxation with guided imagery
Number of subjects: 45

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 45
Study: 9669244

Group type: EXPERIMENTAL
Intervention: Prehospital thrombolysis
Number of subjects: 362

Group type: COMPARATOR
Intervention: Hospital thrombolysis
Number of subjects: 362

Group type: COMPARATOR
Intervention: Single ECG
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Serial ECGs
Number of subjects: 362
Study: 7932682

Group type: EXPERIMENTAL
Intervention: Auditory biofeedback with differing instructions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 2842137

Group type: EXPERIMENTAL
Intervention: Flumazenil (1.0 mg i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total intravenous anesthesia with midazolam and alfentanil
Number of subjects: 0
Study: 29148893

Group type: EXPERIMENTAL
Intervention: Reduced-intensity delayed intensification (protocol III; P-III)
Number of subjects: 1164

Group type: COMPARATOR
Intervention: Standard delayed intensification (protocol II; P-II)
Number of subjects: 1164
Study: 28025434

Group type: EXPERIMENTAL
Intervention: Ischemic stroke patients
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no previous stroke)
Number of subjects: 86
Study: 25635970

Group type: EXPERIMENTAL
Intervention: Prophylactic oral, rectal or vaginal misoprostol
Number of subjects: 248

Group type: COMPARATOR
Intervention: No-treatment option
Number of subjects: 248
Study: 23089080

Group type: EXPERIMENTAL
Intervention: Conventional air-purifying respirator (APR)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Loose-fitting powered air-purifying respirator-hood (PAPR-hood)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (unprotected)
Number of subjects: 16
Study: 20567999

Group type: EXPERIMENTAL
Intervention: ZP-PTH 20 µg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZP-PTH 30 µg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZP-PTH 40 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: FORTEO® injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZP-PTH
Number of subjects: 0
Study: 19018250

Group type: EXPERIMENTAL
Intervention: Surgery (standard open discectomy)
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Nonoperative care
Number of subjects: 1244